Overview
Location
United States, Florida, Sarasota
Employees
11-50
Total raised
$5.5M
Founded date
2006
Funding Rounds 1
| Date | Series | Amount | Investors |
| Sign up to see | Sign up to see | Sign up to see | Sign up to see |
Mentions in press and media 19
| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| Oct 21, 2026 | Lakewood-Amedex Presents Nu-3 Broad-Spectrum Antimicrobial Activity and Low Resistance Potential Data at IDWeek 2026 | Research highlights Nu-3's rapid bactericidal activity against clinically relevant resistant pathogens and its potential as a topical treatment for infected diabetic foot ulcers Lakewood-Amedex highlights promising laboratory findings ... |
| Oct 8, 2026 | Lakewood-Amedex Announces Positive Preclinical Bisphosphocin® Compound Data in Urinary Tract and Pulmonary Infections | Lakewood-Amedex Biotherapeutics (Nasdaq: LABT) reports positive preclinical data for Bisphosphocin® compounds in animal models of urinary tract and pulmonary infection. In an animal model of UTI, intravesical Nu-8 in rodents infected with E... |
| Oct 2, 2026 | Lakewood-Amedex Biotherapeutics Announces Participation in October Conferences | Lakewood-Amedex CEO Kelvin Cooper, Ph.D., will participate in three October conferences, highlighting the Company’s Nu-3 antimicrobial development program. Lakewood-Amedex will showcase Nu-3 and its Bisphosphocin® antimicrobial technology a... |
| Sep 30, 2026 | Lakewood-Amedex Biotherapeutics Announces Positive Data Against Clinical Isolates from Infected Diabetic Foot Ulcers | Lakewood-Amedex reports positive MIC data showing Nu-3 activity against recent clinical isolates from infected diabetic foot ulcers, including resistant pathogens. Nu-3 demonstrated consistent antibacterial activity across tested clinical i... |
| Sep 24, 2026 | Lakewood-Amedex Announces First Patient Dosed in Phase 2a Clinical Trial of Nu-3 for Infected Diabetic Foot Ulcers | Topline data expected in the first quarter of 2027 Lakewood-Amedex doses the first patient in its Phase 2a clinical trial of Nu-3 for mildly infected diabetic foot ulcers, with topline data expected in Q1 2027. Initiation of patient dosing ... |
| Sep 21, 2026 | Lakewood-Amedex Biotherapeutics CEO Issues Shareholder Letter Highlighting Transformational Progress & Outlook for Nu-3 | Strengthened balance sheet through completion of a $7.5 million private placement to support continued clinical advancement Reported positive preclinical safety and tolerability data supporting dose selection for the upcoming Phase 2a clini... |
| Sep 18, 2026 | Lakewood-Amedex Announces IRB Approval to Initiate Phase 2a Clinical Trial of Nu-3 for Infected Diabetic Foot Ulcers | Lakewood-Amedex receives IRB approvals and confirms clinical site readiness to begin its Phase 2a trial of Nu-3 for mildly infected diabetic foot ulcers. Lakewood-Amedex advances Nu-3 into Phase 2a clinical development, evaluating its novel... |
| Sep 8, 2026 | Lakewood-Amedex Biotherapeutics to Present at H.C. Wainwright 28th Annual Global Investment Conference | Lakewood-Amedex will highlight its business and clinical development strategy, recent achievements, and upcoming milestones at the H.C. Wainwright Global Investment Conference. Lakewood-Amedex Biotherapeutics Inc. (NASDAQ:LABT)SARASOTA, FL,... |
| Aug 25, 2026 | Lakewood-Amedex Biotherapeutics Becomes a B2i Digital Featured Company | B2i Digital Campaign to Center on Nu-3, the Upcoming Phase 2a Trial, and the Bisphosphocin® Class Behind It Lakewood-Amedex is advancing Nu-3, a novel topical antimicrobial candidate for infected diabetic foot ulcers, supported by an extens... |
Show more
Reviews 0
FAQ about Lakewood
When was Lakewood founded?
Lakewood was founded in 2006.
How much funding has Lakewood raised?
Lakewood has raised $5.5M in total across 1 funding round.
What has the press written about Lakewood?
Parsers VC has collected 19 articles mentioning Lakewood, among them “Lakewood-Amedex Presents Nu-3 Broad-Spectrum Antimicrobial Activity and Low Resistance Potential Data at IDWeek 2026” (Oct 21, 2026) and “Lakewood-Amedex Announces Positive Preclinical Bisphosphocin® Compound Data in Urinary Tract and Pulmonary Infections” (Oct 8, 2026).
Is Lakewood still active?
Yes, Lakewood is active; its latest activity on Parsers VC dates from Nov 5, 2026.